Galvion and South 8 Technologies Sign Letter of Intent to Collaborate on Lithium-ion Battery Technology for Extreme Cold Environments

South 8 Technologies, a San Diego–based innovator redefining lithium-ion battery performance with its patented LiGas® cell technology, today announced it has signed a Letter of Intent (LOI) with Galvion, a global leader in the design and manufacture of intelligent power and data management solutions, innovative head systems and integrated soldier systems. The LOI represents a shared commitment between two innovative defense and energy organizations to push the boundaries of battery performance through focused research and product development.

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, Pte. Ltd, a biotechnology company developing next-generation T cell receptor (TCR)-based therapies in oncology, today announced that they have entered into a collaboration and license agreement to advance a novel in vivo approach to cell therapy for the treatment of solid tumors. Under the agreement, ImmunoScape will develop a novel Seed-and-Boost immunotherapy that combines Cue Biopharma’s clinically-validated Immuno-STAT T-cell engagers, the CUE-100 series, with ImmunoScape’s proprietary TCRs. The combination therapy is designed to overcome core limitations of existing cell therapies with the potential for establishing a breakthrough standard of care with superior anti-tumor activity, durable T cell persistence and product scalability.